CA-BE-MY-EYES
Be My Eyes, the mobile app that allows anyone to assist visually impaired people through live video calls, today announced Virtual Volunteer™, the first-ever digital visual assistant powered by OpenAI’s new GPT-4 language model.
The new tool from Be My Eyes integrates OpenAI’s latest generative AI technology, with the goal of providing an unprecedented level of accessibility and power to the 253 million people who are blind or have low vision globally.
“We are entering the next wave of innovation for accessibility technology powered by AI. This new Be My Eyes feature will be transformative in providing people who are blind or have low vision with powerful tools to better navigate physical environments, address everyday needs, and gain more independence,” said Mike Buckley, CEO of Be My Eyes. “We are thrilled to work with OpenAI to further our mission of improving accessibility for the 253 million people who are blind or have low-vision, with safe and accessible applications of generative AI.”
The Virtual Volunteer feature will be integrated into the existing app and contains a dynamic new image-to-text generator powered by GPT-4. Users can send images via the app to an AI-powered Virtual Volunteer, which will answer any question about that image and provide instantaneous, conversational visual assistance for a wide variety of tasks.
What sets the Virtual Volunteer tool apart from other image-to-text technology available today is the context it provides, with highly nuanced explanations and conversational abilities not yet seen in the digital assistant field. For example, if a user sends a picture of the inside of their refrigerator, the Virtual Volunteer will not only be able to correctly identify the items within, but also extrapolate and analyze what can be prepared with those ingredients. The tool can also then offer a number of recipes for those ingredients and send a step-by-step guide to prepare them.
This new feature promises to not only better support the blind and low-vision community through the Be My Eyes app, but it will also offer a way for businesses to better serve their customers by prioritizing accessibility. Be My Eyes plans to begin beta testing this with corporate customers in the coming weeks, and to make it broadly available later this year as part of the company’s Accessible CX™ offering.
Since its founding in 2015, Be My Eyes has worked to connect its 6.3 million volunteers to users to assist them with everyday tasks, and the company’s mission is to make the world more accessible for people who are blind or have low vision.
In the near future, Be My Eyes plans to apply this technology to provide people with powerful tools and capabilities to enrich their virtual assistant experience in complex ways – for example, navigating a train system in an unfamiliar place, traveling in a foreign country where translation support is needed, browsing websites and social media platforms, online shopping, and a host of other scenarios to be discovered in testing.
People who are blind or have low vision can register for the wait list in the iOS app. Just like the existing volunteer service, this tool is free for all blind and low-vision community members using the Be My Eyes app.
About Be My Eyes
Based in Denmark and launched in 2015, Be My Eyes is a global community that connects people who are blind or have low vision with sighted volunteers or company representatives. On the app, volunteers assist blind and low-vision users through a live video connection and work together to tackle challenges and handle a wide range of tasks. With the Specialized Help feature, blind and low-vision users can connect with company representatives for accessible customer support. The app harnesses the power of generosity, technology, and human connection so that people who are blind or have low vision can lead more independent lives. Be My Eyes is accessible in more than 150 countries worldwide and in over 180 languages. The app is free and available for both iOS and Android. Learn more at bemyeyes.com and join us on LinkedIn, Twitter, Facebook, Instagram, and TikTok.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005425/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom